Dear colleagues,
we know about the anti-inflammatory and anti-fibrotic properties of MSC, as reviewed e.g. in this article:
https://www.nature.com/articles/s41401-022-00952-0
Mucous membrane pemphigoid (MMP) is a rare chronic autoimmune disorder, often affecting the conjunctiva. The chronic inflammation and progressing fibrosis can lead to blindness. Therapy often requires systemic immunosuppression with dapsone or prednisone or sometimes high-dose prednisone with immunosuppressants (eg, azathioprine, mycophenolate, cyclophosphamide, rituximab) or even IV immune globulin.
Would it make sense to apply MSC topically (e.g. as sub conjunctival injection) in patients with MMP in order to make use of the anti-inflammatory and anti-fibrotic properties of MSC? Or would the effect be -if any- only very temporarily because of the recurrent inflammation induced by the circulating antibodies? What do you think?
Thank you for your thoughts and opinions!